Table 3. Main Outcomes of Multivariable Regression Analysis.
| Variable | No. | HR (95% CI) | P value | Overall P value |
|---|---|---|---|---|
| Relapse | ||||
| Conditioning regimen | ||||
| TBC | 263 | 1 [Reference] | <.001 | |
| TT-BCNU | 275 | 1.79 (1.07-2.98) | .03 | |
| BEAM | 65 | 4.34 (2.45-7.70) | <.001 | |
| NRMa | ||||
| Conditioning regimen | ||||
| TBC | 263 | 1 [Reference] | .03 | |
| TT-BCNU | 275 | 0.50 (0.29-0.87) | .01 | |
| BEAM | 65 | 0.50 (0.20-1.28) | .15 | |
| PFSb | ||||
| Conditioning regimen | ||||
| TBC | 263 | 1 [Reference] | .04 | |
| TT-BCNU | 275 | 1.04 (0.72-1.50) | .86 | |
| BEAM | 65 | 1.74 (1.10-2.75) | .02 | |
| OSc | ||||
| Conditioning regimen (≤6 mo after HCT)a | ||||
| TBC | 263 | 1 [Reference] | .008 | |
| TT-BCNU | 275 | 0.35 (0.17-0.73) | .01 | |
| BEAM | 65 | 0.26 (0.06-1.12) | .07 | |
| Conditioning regimen (>6 mo after HCT)d | ||||
| TBC | 232 | 1 [Reference] | .002 | |
| TT-BCNU | 257 | 1.54 (0.93-2.55) | .10 | |
| BEAM | 62 | 2.73 (1.56-4.76) | <.001 | |
| Missing | 3 | 4.08 (0.53-31.55) | .18 | |
Abbreviations: BEAM, carmustine, etoposide, cytarabine, melphalan; HCT, hematopoietic cell transplant; HCT-CI, hematopoietic cell transplant comorbidity index; HR, hazard ratio; KPS, Karnofsky performance status; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival; TBC, thiotepa, busulfan, cyclophosphamide; TT-BCNU, thiotepa, carmustine.
a
NRM adjusted for significant covariates: age, HCT-CI.
b
PFS adjusted for significant covariates: age, KPS, disease status/time from diagnosis to HCT.
c
OS adjusted for significant covariates: age, HCT-CI, disease status/time from diagnosis to HCT.
d
The 6-month time frame was chosen as the cutoff OS based on the maximum likelihood value in the Cox model.